Investigation of the efficacy of Risperidone in the treatment of developmental stuttering in Persian-speaking children aged 5 to 10 years

Phase 3

Recruiting

• Conditions: Stuttering.; F80.81; Childhood onset fluency disorder

• Registration Number: IRCT20240527061909N1
• Lead Sponsor: Babol University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2024-08-26

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Age range from 5 to 10 years
2. Having a diagnosis of developmental stuttering disorder based on the score of the SSI-3 test and the therapist's speech diagnosis
3. Absence of any language, speech or reading disorders other than stuttering
4. Absence of any kind of neurological, movement, vision, hearing, mental-cognitive problems in the past or present
5. Not taking drugs affecting cognitive function or stuttering, in the last month or during research
6. Absence of history of speech therapy treatment at least in the last 3 months

Exclusion Criteria

The individual's unwillingness to cooperate in any stage of the research.

Study & Design

• Study Type: interventional
• Study Design: Not specified